+44 (0) 1223 435380 enquiries@teraview.com

TeraView is Granted Its 50th Patent for Pioneering Work in Terahertz Technology and Its Applications

TeraView, (www.teraview.com ) the global leader in terahertz technology for the pharmaceutical and analytical industries, announces the award of its 50th patent. Recent patents cover areas such as terahertz imaging of pharmaceutical tablets and high performance terahertz sources. Along with an expanding customer base, these grants further underpin TeraView’s leadership in both the development of terahertz products and their implementation to solve specific business issues for our customers.

A key component to TeraView’s intellectual property is its applications know-how focussed upon solutions to industry-specific challenges. In pharmaceuticals, TeraView has developed proprietary methods for determining polymorphism, coating thickness and density, core integrity and other tablet attributes which correlate with product performance vital to the rapid development of high quality drugs compliant with regulatory standards. Combined with our patented tablet imaging and in-line inspection products, these capabilities provide pharmaceutical partners with process knowledge not available with existing techniques.

Similarly in the security, defense and medical sectors, the company’s pioneering work has led to new means of detecting and identifying explosives and cancer with terahertz light, which is being used in both of our current products in the field and in new developments.

The depth and breadth of this intellectual property is the result of substantial company investment over the past decade, and is core to our successful business model. TeraView has assembled at team of world-class scientists committed to closely support customers, from evaluation through to deployment, as well as on-going support of our offerings.

Another key component of TeraView’s portfolio covers critical aspects of product performance, notably the unrivalled signal to noise and bandwidth of our imagers and spectrometers which are fundamental enablers for industrial applications. The company has made proprietary advances in the generation, detection and manipulation of terahertz light using both pulsed and continuous wave platforms. These unique capabilities are important for laboratory and field-deployable products, and are driven by our technology and product development teams built up by the company over the past several years.

Dr Don Arnone, Chief Executive Officer of TeraView commented: “The award of our 50th patent is a significant milestone, and we are proud of our team and their achievements which have put us in this leadership position. Most importantly, our intellectual property has been driven by market requirements, and its real value is our ability to put it to work for our customers and support their business needs, now and in the future.”

Professor Sir Michael Pepper, Chief Scientific Officer of TeraView noted: “TeraView’s success in developing markets for terahertz is underpinned by an innovative internal program which actively generates our IP. Consequently we have a very strong patent position to keep us in the forefront as we respond to new applications”.

Note for editors

Terahertz light is unique in its ability to non-destructively image tablets and other dosage forms. X-ray and infrared frequently lack sensitivity or penetration and cannot produce such images without first destroying the tablet. TeraView currently works closely with blue chip customers in the pharmaceutical and other industries who are exploring the use of terahertz in product and process development and quality control of finished product in manufacturing.

About TeraView (www.teraview.com )

TeraView is the world’s first company devoted to the application of terahertz light for spectroscopy and imaging in pharmaceutical drug development and manufacture. TeraView’s technology can improve the quality of pharmaceutical products and decrease the risk of regulatory non-compliance, leading to potentially safer tablets and savings arising from faster times to market and volume production of higher quality, stable products. Other markets for the technology exist in early stage cancer detection, defense and industrial inspection which are explored via commercial partners. Headquartered in Cambridge, UK, TeraView was spun-out of the Toshiba Cambridge Research Laboratory in April 2001. Sales and support are available throughout Europe, North America and the Far East either directly or through a network of distributors.